Pharmosa Biopharm Inc.

As of June 30, 2026, Pharmosa Biopharm Inc. carries a market capitalization of 4.97B, placing it among publicly traded companies globally. Its enterprise value stands at 4.38B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Pharmosa Biopharm Inc. has 129.18M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 92.65, and the price-to-book ratio stands at 3.64.

These figures are as of June 30, 2026. The EV/Sales ratio of 82.07 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 4.38B versus a market cap of 4.97B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Pharmosa Biopharm Inc. maintains a current ratio of 12.45, meaning it holds 12.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 24.95, indicating elevated leverage, while an interest coverage ratio of -143.06 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Pharmosa Biopharm Inc. posted a negative return on equity (ROE) of -22.83, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -19.03, reflecting losses generated across the asset base. The company generates approximately 1.53M in revenue per employee across its workforce of 35.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.28 indicates how many times Pharmosa Biopharm Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 22, 2026, Pharmosa Biopharm Inc.'s stock has declined approximately 54.68% over the past 52 weeks. The 50-day moving average sits at 31.09, while the 200-day moving average is 37.52.

Over the twelve months ended June 30, 2026, Pharmosa Biopharm Inc. generated 53.38M in revenue and converted that into -351.33M in net income, yielding earnings per share of -2.73. EBITDA reached -367.67M, while operating income came in at -406.79M.

As of June 30, 2026, Pharmosa Biopharm Inc. holds 933.28M in cash and equivalents against 340.89M in total debt, resulting in a net debt position of -583.28M. Total book value stands at 1.37B, with working capital of 934.45M providing operational flexibility.

Pharmosa Biopharm Inc. produced -319.30M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -179.93M in capital expenditures, free cash flow totaled -499.23M - equivalent to -3.89 per share.

Over the twelve months ended June 30, 2026, Pharmosa Biopharm Inc. posted a gross margin of 19.84, reflecting its pricing power and cost economics. The operating margin of -762.03 and net profit margin of -658.14 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -10.09: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -2.66, meaning Pharmosa Biopharm Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Pharmosa Biopharm Inc.'s most recent stock split took place on July 10, 2023 with a 407:416 split ratio.

As of June 30, 2026, Pharmosa Biopharm Inc. has an Altman Z-Score of 6.92, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.